Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001209191-21-038978

Director sold 94,378 shares at an average $70.35 ($6,639,523)

  • Director acquired 94,378 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Tessier-Lavigne Marc · Director

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2021-06-07 Exercise or conversion : show line 1 in the form +39,303 $18.00 $707,454 2,583,673 D
2021-06-07 Exercise or conversion : show line 2 in the form +27,830 $18.92 $526,544 2,611,503 D
2021-06-07 Exercise or conversion : show line 3 in the form +27,245 $19.50 $531,278 2,638,748 D
2021-06-07 Sale : show line 4 in the form −93,678 $70.35 $6,589,779 2,545,070 D
2021-06-07 Sale : show line 5 in the form −700 $71.06 $49,744 2,544,370 D
Open-market sales · 94,378 sh · avg $70.35 · $6,639,523

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2021-06-07 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −39,303 7,862 D
2021-06-07 Exercise or conversion : show line 7 in the form Stock Option (right to buy) −27,830 0 D
2021-06-07 Exercise or conversion : show line 8 in the form Stock Option (right to buy) −27,245 0 D
Loading xslF345X03/doc4.xml…